X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 55 filers reported holding X4 PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,431,173 | -48.4% | 3,147,865 | -8.1% | 0.01% | -45.5% |
Q2 2023 | $6,644,477 | +73.7% | 3,424,988 | -22.1% | 0.02% | +69.2% |
Q1 2023 | $3,824,927 | -11.7% | 4,396,468 | +0.8% | 0.01% | -18.8% |
Q4 2022 | $4,331,110 | -69.3% | 4,361,641 | -47.2% | 0.02% | -42.9% |
Q3 2022 | $14,112,247 | +535.6% | 8,252,920 | +258.7% | 0.03% | +600.0% |
Q2 2022 | $2,220,201 | -44.9% | 2,300,934 | -0.1% | 0.00% | -33.3% |
Q1 2022 | $4,029,845 | +52.8% | 2,302,680 | +99.9% | 0.01% | -14.3% |
Q4 2021 | $2,638,000 | -15.5% | 1,151,819 | +95.1% | 0.01% | -22.2% |
Q3 2021 | $3,123,000 | -57.7% | 590,269 | -48.1% | 0.01% | -18.2% |
Q2 2021 | $7,390,000 | +50.9% | 1,136,832 | +99.8% | 0.01% | -26.7% |
Q1 2021 | $4,898,000 | +33.9% | 568,847 | -0.0% | 0.02% | +36.4% |
Q4 2020 | $3,659,000 | -1.0% | 568,995 | +4.2% | 0.01% | -15.4% |
Q3 2020 | $3,697,000 | -62.0% | 546,078 | -47.6% | 0.01% | -31.6% |
Q2 2020 | $9,722,000 | -3.2% | 1,043,068 | +3.9% | 0.02% | -24.0% |
Q1 2020 | $10,044,000 | – | 1,004,326 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,682,000 | 3.48% |
Sio Capital Management, LLC | 804,597 | $6,928,000 | 1.41% |
Bain Capital Life Sciences Investors, LLC | 2,119,540 | $18,249,000 | 1.03% |
SV Health Investors, LLC | 311,490 | $2,682,000 | 1.00% |
Monashee Investment Management LLC | 574,712 | $4,948,000 | 0.76% |
Ikarian Capital, LLC | 2,614,988 | $22,515,000 | 0.76% |
Abingworth LLP | 229,885 | $1,956,000 | 0.68% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,884,000 | 0.67% |
BVF INC/IL | 1,091,579 | $9,398,000 | 0.35% |
Endurant Capital Management LP | 151,996 | $1,309,000 | 0.34% |